Apple’s iOS 12 Update Set To Improve 911 Emergency Calls

Dow 30 component Apple (AAPL) revolutionized personal technology with the introduction of the Macintosh in 1984. Today, Apple leads the world in innovation with iPhone, iPad, Mac, Apple Watch and Apple TV. Apple’s four software platforms — iOS, macOS, watchOS and tvOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay and iCloud. Apple’s more than 100,000 employees are dedicated to making the best products on earth, and to “leaving the world better than they found it.”

iOS Help On The Way

With Apple’s new iOS 12 update, set to come out later this year, iPhone users in the U.S. who call 911 will automatically have their location data securely shared with first responders in an effort to reduce emergency response times in an effort to improve the overall outcome.

Nearly 80% of 911 come from mobile devices, and with landline-era infrastructure still in place, accurately locating a mobile caller’s location can be difficult for 911 centers. In 2015, Apple launched HELO (Hybridized Emergency Location) which uses cell towers and on-device data sources such as GPS and WiFi Access Points to estimate a mobile 911 callers location, in order to help improve the challenge. Looking to improve 911 response time, Apple will now also use emergency technology company RapidSOS’s Internet Protocol-based data pipeline along with HELO to improve the 911 centers response time.

What’s “Cookin’?”

Tim Cook, Apple’s CEO stated, “Communities rely on 911 centers in an emergency, and we believe they should have the best available technology at their disposal. When every moment counts, these tools will help first responders reach our customers when they most need assistance.”

With these improvements, Apple is keeping a focus on privacy so that user data will not be used for any non-emergency purpose. The 911 responding center will only have access to the user’s location during the duration of an emergency call.

FCC Likes?

Tom Wheeler, FCC Chairman from 2013 to 2017 stated, “This new functionality is an example of how companies and first responders can use technology to dramatically improve public safety. Lives will be saved thanks to this effort by Apple and RapidSOS.”

Learn more about Apple and track its ongoing progress at Vista Partners Apple (AAPL) Coverage Page.

Free stock photo of fashion, man, person, buildings

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Apple’s iOS 12 securely and automatically shares emergency location with 911

..

www.apple.com

Read Full Article



Atossa Reports Progress & Results Timeline For Male Breast Enlargement Trial

Seattle based Atossa Genetics Inc. (ATOS) (“Atossa”) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.  Atossa is developing topical Endoxifen for a condition in men called gynecomastia, which is male breast enlargement.

Mayo Clinic Research

According to the Mayo Clinic, 25% of men in the U.S. between the ages of 50-69, or approximately 10 million men, suffer from gynecomastia. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen.  For example, in prostate cancer treatment, testosterone is suppressed with androgen deprivation therapy resulting in higher estrogen levels that usually triggers gynecomastia. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014, BJU International). There is no FDA-approved pharmaceutical to treat gynecomastia. Current therapeutic approaches in these patients include the daily use of oral estrogen-suppressing medications and prophylactic breast bud irradiation which is often repeated.

 

 

 

 

 

Progress Announced!

Today, Atossa announced progress in its Phase 1 study of its proprietary topical Endoxifen in men as it has reported that it has completed dosing and clinical visits. The objectives of the placebo-controlled, repeat dose study of 24 healthy male volunteers are to assess the pharmacokinetics of a proprietary topical Endoxifen dosage form over 28 days, as well as to assess safety and tolerability.

Steve Quay, Ph.D., M.D., President and CEO of Atossa stated, “We are now proceeding to the final stages of this study, which are to complete analysis of blood samples and then collect and analyze the data. We expect to report preliminary results from the study in the next quarter.”

Atossa Reaches Further

In addition to gynecomastia, Atossa is also developing its proprietary topical Endoxifen to reduce Mammographic Breast Density (MBD), which has been shown in studies conducted by others to be an independent risk factor for developing breast cancer. To date, 34 U.S. states have enacted laws requiring that findings of MBD be communicated to the patient. And according to the National Cancer Institute, approximately 10 million women in the U.S. have high breast density (BI-RADS level C or D with “D” being the highest). Although oral tamoxifen has been shown to reduce MBD, the benefit-risk ratio is generally not acceptable to most patients. For example, it is estimated that only ~ 2% of women at high-risk of developing breast cancer, including those with MBD, take oral tamoxifen to prevent breast cancer because of the risks of, or actual side-effects of, oral tamoxifen. There is no FDA-approved treatment for MBD.

Atossa is planning a Phase 2 study of its topical Endoxifen in women with MBD. The study will be conducted at Stockholm South General Hospital in Sweden and will be led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.

The primary endpoint of this study is to determine if topical Endoxifen administration results in an individual change in MBD, which will be measured after three and six months. Secondary endpoints are safety and tolerability. The objective of the study is to determine the effect size on MBD between the placebo and active groups, which will permit sample size calculations in a future Phase III study. Enrollment is anticipated to be completed by the end of 2018.

Shares Surge

Shares of Atossa (ATOS) surged to as high as $3/share and traded ~2.62 million shares today and closed at $2.63/share up +5.2%.

Analyst Update

Maxim Group’s Biotechnology Analyst Jason McCarthy issued an update report and maintained his “Buy rating” and his $10/price target.

Learn More

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has completed dosing and clinical visits in its Phase 1 study of its proprietary..

finance.yahoo.com

Read Full Article



DOE Invests $64 Million Towards Nuclear Technology Advancement

$64 million will be given in awards for an advanced nuclear energy technology to DOE national laboratories, industry, and 39 U.S. universities in 29 states from the U.S. Department of Energy. The DOE’s Office of Nuclear Energy has selected a total of 89 projects for funding of nuclear energy research, facility access, and crosscutting technology and infrastructure development.

The Nuclear Energy University Program, the Nuclear Energy Enabling Technologies, and the Nuclear Science User Facilities program are the three DOE programs that the awards are spread between.

NUEP was awarded $47 million to help support 63 U.S. university-led research projects. Another $5 million was awarded to NEUP to back 18 university-led projects for the research reactor and infrastructure improvements that are meant to provide integral safety, performance, and educational upgrades to some of the nation’s university research reactors.

NEET was awarded $5 million for 5 research and development projects that will be led by the DOE national laboratories, industry, and universities. The research will be conducted over crosscutting nuclear energy challenges.

Under NSUF, the DOE selected on industry and two university-led projects that will receive $6.6 million for research, facility access costs and expertise for investigation of important nuclear fuel and material applications.

Time Lapse Photography of Mountain

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Department of Energy Invests $64 Million in Advanced Nuclear Technology

..

www.energy.gov

Read Full Article



Online Survey Company, SurveyMonkey, Registers for IPO

SurveyMonkey, a U.S. online survey company, announced its confidential registration for an initial public offering (IPO) with the Securities and Exchange Commission. The company has not determined the number of shares offered or the price range or the proposed offerings. Sources reported that the survey company had hired JPMorgan Chase, an investment bank, to help with the preparations for an IPO last month. Alphabet’s CapitalG and Tiger Global Management are investors in the company.

SurveyMonkey is based in San Mateo, CA and has nearly 3 million daily users. The company was formerly run by Dave Goldberg, who is the late husband of Sheryl Sandberg, the Chief Operating Officer of Facebook.

Sliced Avocado on Brown Wooden Board

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

SurveyMonkey confidentially files for IPO

U.S. online survey company SurveyMonkey said it had confidentially registered for an initial public offering with the Securities and Exchange Commission…

www.cnbc.com

Read Full Article



Is “Gaming Disorder” Considered a New Mental Health Problem Now?

The World Health Organization has announced that compulsively playing video games is now considered a mental health condition, verifying the fears of many parents.

The World Health Organization or WHO, hopes that in identifying “gaming disorder” as a separate addiction, will assist government, health care workers, and families in being more vigilant and prepared for identifying the risks of the condition. The condition is still extremely rare, having no more than 3% of gamers affected.

While gaming disorder has been accepted as new problem with scientific evidence to back it, Dr. Joan Harvey of the British Psychological Society, is concerned about unnecessary concern among parents of video gamers that the new disorder might cause.

“People need to understand this doesn’t mean every child who spends hours in their room playing games is an addict, otherwise medics are going to be flooded with requests for help,” she said.

Many believe that the new classification of the disorder is imperative to helping the people hooked on video games seek help, especially since they are typically teenager or young adults unwilling to seek help for themselves.

The addiction seems to be best treated using psychological therapies, although some medicines might work too.

While WHO has approved the proposal of the addiction, the American Psychiatric Association has not declared gaming disorder as a new mental health problem stating that it is “a condition warranting more clinical research and experience before it might be considered for inclusion”.

The majority of the scientific literature on compulsive gamers has been based off of evidence from young Asian men. The studies have shown that people who are consumed in Internet games, have certain pathways in the brain that are triggered in a direct, intense way, similar to the way a drug addicts brain is affected by a given substance.

“If (video games) are interfering with the expected functions of the person — whether it is studies, whether it’s socialization, whether it’s work — then you need to be cautious and perhaps seek help.” – Dr. Mark Griffith, Professor of Behavioral Addiction, Nottingham Trent University

Person Holding Doughnut With Sprinkles

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

The World Health Organization Now Considers ‘Gaming Disorder’ a Unique Mental Health Condition

The World Health Organization said that compulsively playing video games now qualifies as a new mental health condition…

time.com

Read Full Article



“Hello Volatility” Vista Partners Weekly Market Update 6-16-18

Vista Partners has published “Hello Volatility” Vista Partners Weekly Market Update 6-16-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies & “Investor Picks”, where we have begun to selectively add those companies/ideas that we are receiving from investors around the world.

Newsletter topics include but are not limited to the following: investing, banks, world news, entertainment & movie industry, cryptocurrencies, healthcare, biotech, mining, technology, cybersecurity, & consumer trends.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

 

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




The Fed Raises Interest Rates As Expected

No shocker for the markets here as The Fed raised interest rates for the seventh time since the financial crisis. The new target range for interest rates increased by .25% to a new range if 1.75%-2%. This is the highest it has been since September of 2008.

All eight of the voting members of the FOMC voted in favor of this decision. The Federal Reserve has stated that in raising the benchmark interest rate, the economy is growing at a “solid” rate and improvement from the May characterization of an economy that is growing at a “moderate” rate. The Fed also cited that there has been a “strong” gain in jobs in recent months, and its data suggests that household spending has increased and fixed investments of businesses are continuing strong growth.

The change in language from the Federal Reserves May report to June report suggests that the Fed officials see monetary policy nearing its neutral rate setting, that is the rate of interest at which the economy experiences full employment and price stability, or 2% inflation.

In its most recent summary of economic projections, the Fed’s outlook for growth and inflation for this year has been raised, and the expectations for unemployment rate have decreased.

Taking a look at employment rates, the Fed officials lowered the median expectation rate for unemployment for the year from 3.8% to 3.6% in March. The rate has also been lowered from 2019 to 2020 from 3.6% to 3.5%.

The Fed now forecasts an economic growth of 2.8% in 2018, raising previous year predictions by 0.07%. The expected growth rate of the U.S. economy for 2019 is 2.4% and 2% for 2020.

Man Wearing Blue Blazer

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Fed hikes rates, signals two more for 2018

The Fed hiked rates and updated its forecasts…

finance.yahoo.com

Read Full Article



Comcast Makes Competitive Offer For Fox In Face Off With Disney

The largest provider of cable television in the nation, Comcast, made an offer of $65B in cash to buy 21st Century Fox’s film and TV studios. The bid comes after the already existing Disney bid of $52.4B, all stock. Movies franchises such as Deadpool, X-Men, Planet of the Apes, and Ice Age all belong to Fox. The combination of Comcast and Fox would join Fox to NBC Universal properties and NBC TV channels that include Bravo and SyFy.

Whichever company purchases Fox, will most likely become the controlling owner of Hulu, which is currently 30% owned by each of the three mentioned companies. Hulu seems to be a very important part of the deal.

When broken down, the Comcast offer comes out to $35 per share in cash, which according to Comcast is a 19% premium over the Disney offer. Along with the purchase, Comcast has proposed to pay the $2.5 billion breakup fee Fox had agreed with Disney upon, and the $1.53 billion fee that would’ve been paid to Disney.

Fox has stated that its agreement with Disney still stands but it “will carefully review and consider the Comcast proposal.”

The new deal comes almost a day after the ruling of a federal judge that the telecommunication giant AT&T could purchase Time Warner, just the first of what is predicted to be an onrush of deals brought on by the traditional entertainment powerhouses and service providers looking to outwrestle the increasing competition of Google, Facebook, and Netflix.

With this deal comes a threat to a glorious Marvel reunion. Disney, film right owners to the Avengers, would have the power to unify the comic-book universe with Fox’s rights to X-men and the Fantastic Four.

Disney’s acquisition of Fox represents the epicenter of Disney’s streaming endeavors, and Comcast entering the Fox sweepstakes is a game of high-stakes poker that could change the course of the media and streaming landscape for decades to come, depending on which direction this deal heads.” – Daniel Ives, an analyst at GBH Insights.

Free stock photo of food, sweet, snack, popcorn

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Comcast offers $65 billion to snake Fox from Disney

Comcast wants to sway 21st Century Fox away from Disney with a richer offer…

www.cnet.com

Read Full Article



Merck’s KEYTRUDA Gains Additional Approval From FDA

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the leading edge of research.

Merck recently announced the U.S. Food and Drug Administration’s approval of the company’s anti-PD-1 therapy KEYTRUDA®. The therapy is used to treat patients who have recurrent or metastatic cervical cancer with disease advancement on or after chemotherapy and with tumors that express PD-L1. The indication for the use of this therapy is approved under the FDA’s accelerated approval regulations that are based on both tumor response rate and the durability of response.

KEYTRUDA is now the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer, providing an important new second-line option for certain patients with this disease. This approval also marks the first indication for KEYTRUDA in a gynecologic cancer and reflects our ongoing commitment to bring forward innovative treatment options across a broad range of cancers, including cancers that disproportionately affect women.” -Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories

With KEYTRUDA, some immune-mediated adverse reactions did occur. Those included were as follows: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, severe skin reactions, and solid organ transplant rejection.

To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page. 

Free stock photo of landscape, nature, sky, clouds

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

View of City Street

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)

Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose..

finance.yahoo.com

Read Full Article



Breast Cancer Innovator Atossa Genetics Adds Former Pfizer & Janssen Pharmacuetica NV Execs To SAB

Seattle based Atossa Genetics Inc. (ATOS) (“Atossa”) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.  This week, Atossa appointed two additional pharmaceutical executives to its strategic advisory board (“SAB”) as they named former Pfizer executive, Dr. Makarand (Mak) Jawadekar and Dr. Ajit Shetty, Chairman of the Belgium-based Flemish Institute of Biotechnology and former Janssen Pharmaceutica NV executive. The board is positioned to play a key role in a number of important strategic initiatives in accelerating the clinical development of Atossa’s programs.

Steven Quay, Ph.D., MD, President and CEO of Atossa stated, “We are very excited to have both Dr. Jawadeker and Dr. Shetty join our advisory board.  Each of these lauded industry veterans brings unique sets of talents and experiences to our company. Their insights and direction will be invaluable in developing our strategic initiatives to advance our therapeutics.

Dr. Mak Jawadekar’s professional career at Pfizer, Inc. spanned 28 consecutive years, most recently as a Director, Portfolio Management. During his career at Pfizer, he was responsible for the Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies and has extensive experience in creating and cultivating external partnerships and alliances in this area. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota. Mak was honored with an honorary D.Sc. degree by DYP Mumbai University, recommended by the President of India in Feb 2011. His years of experience with Pfizer Global R&D includes Solids R&D, Drug Product Formulation/ Dosage Form/Drug Delivery development, Clinical Trials Supply Manufacturing, and Scale-up and Technology Transfer & Research Pharmacy functions. At Pfizer he was also a bench scientist, working on many challenging commercial formulations which became multibillion-dollar products.

Dr. Shetty spent his 40-plus year career at Janssen Pharmaceutica NV in Belgium (a Johnson & Johnson company) in which he drove the expansion of the Janssen Group of Companies through geographical expansion, new product introduction, and significant market share growth. In his prior capacity as President of Janssen Pharmaceutica USA, Dr. Shetty launched Janssen USA into the largest pharmaceutical market. Currently, Dr. Shetty is Chairman of the Belgium-based Flemish Institute of Biotechnology, one of the world’s top-ten research institutions. In 2008, he was awarded the title of Baron by the King of Belgium and in 2004 was elected Manager of the Year by Trends/Flemish Management Association. He is a member of the Board of Directors at Agile Therapeutics, Actinium Pharmaceuticals, and is a member of the Board of Trustees of Carnegie Mellon University.

 

 

 

 

 

 

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced the appointment of two additional pharmaceutical executives to its strategic advisory..

finance.yahoo.com

Read Full Article